Aaron LeBeau, PhD
Dr. LeBeau is an Assistant Professor in the Department of Pharmacology and a Visiting Scientist at the Mayo Clinic in Rochester, MN. He was a double major at the University of Arizona receiving B.S. degrees in Molecular and Cellular Biology and Chemistry with a minor in Classical Art and Archaeology. Dr. LeBeau then received his Ph.D. from the Johns University School of Medicine working with Samuel Denmeade, MD in the Department of Pharmacology and Sidney Kimmel Comprehensive Cancer Center. After graduate school, he was a Department of Defense Postdoctoral Fellow at the University of California San Francisco in the Department of Radiology under the guidance of Henry Vanbrocklin, Ph.D. Dr. LeBeau has been faculty at the University of Minnesota since 2014 where he leads his multi-R01 funded research program. An expert in the development of prostate cancer therapeutics, Dr. LeBeau was awarded a 2018 Challenge Award from the Prostate Cancer Foundation – the first in the history of the University of Minnesota.
Prostate cancer, antibody phage display, nuclear imaging, drug development
Awards & Recognition
Paul Calabresi K12 Clinical Sciences Award, 2016
Prostate Cancer Foundation (PCF) Young Investigator Award, 2013
Tapan Chaudhuri Award from the Society of Nuclear Medicine, 2012
Department of Defense Prostate Cancer Research Program Postdoctoral Fellowship, 2010
Assistant Professor, Department of Pharmacology
Faculty, MS and PhD Programs in Pharmacology
Visiting Scientist, Mayo Clinic
Postdoctoral Fellow, UCSF, San Francisco, CA
PhD, Johns Hopkins University
BS/BS, University of Arizona, Tucson, AZ, Molecular and Cellular Biology / Chemistry
The goal of our research is to develop novel antibody-based molecular imaging agents and targeted therapeutics for metastatic prostate cancer. Our laboratory specializes in antibody phage display. This technique allows us to rapidly identify antibody fragments against cancer-associated antigens using our in-house human antibody libraries. We have also developed non-human single-domain antibody libraries from naïve camelids and nurse sharks. When coupled to radioisotopes, our antibodies are employed as positron-emission tomography (PET) and single-emission computed tomography (SPECT) nuclear imaging agents and as radioimmunotherapy agents. Additionally, we are developing novel cell-based therapeutics for prostate cancer by engineering chimeric antigen receptor (CAR) Natural Killer (NK) cells for adoptive cellular immunotherapy.
Our laboratory is a tight knit community. Everyone helps each other and provides support when a lab member is presented with a challenge. We also respect work-life balance. Nothing makes a scientist more unproductive than over working and we respect the need for developing outside of the laboratory. Because of our positive atmosphere, we are highly productive and our trainees routinely present their scientific findings at both domestic and international conferences ranging from Atlanta to Hong Kong. Our students have won many prestigious awards including a Department of Defense Prostate Cancer Research Program Predoctoral Award – the first such award in the history of the University of Minnesota.